scholarly journals RYR2 mutation in non‐small cell lung cancer prolongs survival via down‐regulation of DKK1 and up‐regulation of GS1‐115G20.1 : A weighted gene Co‐expression network analysis and risk prognostic models

2021 ◽  
Author(s):  
Wenjun Ren ◽  
Yongwu Li ◽  
Xi Chen ◽  
Sheng Hu ◽  
Wanli Cheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Network Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Models ◽  
Small Cell Lung ◽  
Down Regulation

Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer

2011 ◽  
Vol 39 (3) ◽  
pp. 3029-3035 ◽  
Author(s):  
Na Li ◽  
Jian-ping Zhang ◽  
Shan Guo ◽  
Jie Min ◽  
Li–li Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Down Regulation ◽  
Β3 Integrin

Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells

2014 ◽  
Vol 322 (2) ◽  
pp. 345-354 ◽  
Author(s):  
Chun-Liang Tung ◽  
Hsien-Chun Chiu ◽  
Yi-Jun Jian ◽  
Yun-Ting Jian ◽  
Chien-Yu Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Cells ◽  
Cell Lung Cancer ◽  
Hsp90 Inhibitor ◽  
Small Cell ◽  
Lung Cancer Cells ◽  
Small Cell Lung ◽  
Down Regulation

Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1

2017 ◽  
Vol 398 (7) ◽  
pp. 785-792 ◽  
Author(s):  
Jian-Hui Chen ◽  
Yu-Long Zheng ◽  
Chuan-Qin Xu ◽  
Li-Zhi Gu ◽  
Zong-Li Ding ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Valproic Acid ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Luciferase Reporter ◽  
Small Cell Lung ◽  
Down Regulation ◽  
Over Expression ◽  
Protein Levels

Abstract Valproic acid (VPA) has been suggested to be a histone deacetylase inhibitor (HDACI). Our present study revealed that VPA at 1 mm, which had no effect on cell proliferation, can significantly increase the sensitivity of non-small cell lung cancer (NSCLC) cells to cisplatin (DDP). VPA treatment markedly decreased the mRNA and protein levels of ABCA1, while had no significant effect on ABCA3, ABCA7 or ABCB10. Luciferase reporter assays showed that VPA can decrease the ABCA1 promoter activity in both A549 and H358 cells. VPA treatment also decreased the phosphorylation of SP1, which can bind to −100 and −166 bp in the promoter of ABCA1. While the phosphorylation of c-Fos and c-Jun were not changed in VPA treated NSCLC cells. Over expression of HDAC2 attenuated VPA induced down regulation of ABCA1 mRNA expression and promoter activities. Over expression of HDAC2 also attenuated VPA induced DDP sensitivity of NSCLC cells. These data revealed that VPA can increase the DDP sensitivity of NSCLC cells via down regulation of ABCA1 through HDAC2/SP1 signals. It suggested that combination of VPA and anticancer drugs such as DDP might be great helpful for treatment of NSCLC patients.

Abstract 4912: Systematic, comparative network analysis on non-small cell lung cancer

2012 ◽  
Author(s):  
Serene Wong ◽  
Max Kotlyar ◽  
Dan Strumpf ◽  
Nick Cercone ◽  
Frances A. Shepherd ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Network Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Comparative Network Analysis

scholarly journals Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups

Lung Cancer ◽  
2015 ◽  
Vol 90 (2) ◽  
pp. 281-287 ◽  
Author(s):  
Xiaofei Wang ◽  
Lin Gu ◽  
Ying Zhang ◽  
Daniel J. Sargent ◽  
William Richards ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Models ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document